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Therapeutic Options for Localized Carcinoma ofthe Prostate: 
The Role of External Beam Radiation Therapy 
Mark S. Khil, MD,* and Jae Ho Kim, MD, PhD' 
During the last three decades the use of ionizing radiation, hoth external heam radiotherapy and 
interstitial radionuclide implant (hrachytherapy), has greatly increased for the treatment of cancer of 
the prostate. The increased use of radiation therapy is in part due to the technological advance of 
high-energy megavoltage units as well as the steadily improving long-term results of radiotherapy. 
Because ofthe comparable tumor control rates, patients wdh early stage prostate cancer have several 
therapeutic options for curative treatment including radical prostatectomy, external beam radiation 
therapy, and interstitial hrachytherapy. The role of external heam radiotherapy is discussed in terms 
ofthe primary management of early and locally advanced prostate cancers as well as the treatment 
of residual or recurrent disease after prostatectomy. A new approach combines antimitotic chemo-
therapeutic agents and radiation therapy for the treatment of locally advanced cancers of the 
prostate. (Henry Ford Hosp Med J 1992;40:103-7) 
P rostate cancer is the second most common malignant dis-ease in American men, and the incidence increases each 
decade after the age of 50. Approximately 122,000 new cases of 
prostate cancer were expected to be diagnosed in 1991. A l -
though 60% of these patients will have localized disease, 32,000 
deaths are predicted (1), 
The use of ionizing radiation in the treatment of adeno-
carcinoma of the prostate, both by external beam (telether-
apy) and by interstitial implant (hrachytherapy), has greatly in-
creased during the last three decades. Of more than 200 patients 
with cancer of the prostate seen annually in our departmenf over 
50% are being evaluated for definitive radical radiation therapy 
for localized disease. Our purpose is to review this treatment and 
to emphasize the possibility of cure with extemal beam radio-
therapy. 
Historical Perspective 
Reports of extemal beam radiation therapy from the 1930s 
through the 1950s dealt mainly with results obtained with 
orthovoltage (250 KVP) radiation (2,3). This treatment deliv-
ered maximum energy in the skin and subcutaneous tissues with 
excessive scattering of radiation; the delivery of a tumoricidal 
dose to the prostate was not always possible without unaccept-
able damage to the skin and sunounding normal tissue. Despite 
these limitations. Smith and Pierson (4) and Widmann (5) re-
ported relatively good results in the relief of pain associated 
with bony metastases, and the latter presented impressive results 
in 82 cases with advanced local neoplasm treated for palliation 
of symptoms. Al l forms of treatment were eclipsed in 1941 
when Huggins et al (6) showed that the growth of prostatic carci-
noma could be retarded by androgen deprivation. Later, how-
ever, as the limitations of hormonal treatment became apparent, 
interest renewed in the radiotherapeutic management of the dis-
ease. In 1952, Flocks et al (7) at the University of Iowa showed 
that the instillation of a short-lived radionuclide, gold colloidal 
suspension (' '^Au), directiy into the neoplasm and/or peri-
prostatic soft tissues following subtotal resection decreased the 
local recunence rate. 
The use of ionizing radiation, stimulated by the report of 
Flocks et al, and the development of a high-energy megavoltage 
x-ray machine prompted renewed interest in die possible use of 
extemal beam radiotherapy. The availability of new megavolt-
age radiation therapy units (> 1 MeV) allowed the delivery ofa 
high tumoricidal dose to the prostate without excessive damage 
to the adjacent normal tissues—skin, subcutaneous tissues, and 
bones. In 1962 Bagshaw and Kaplan (8) at Stanford University 
presented their observations on the application of extemal beam 
inadiation as definitive treatment for carcinoma of the prostate. 
This was followed in the next two decades by other reports 
which attested to the radiocurabitity of carcinoma of the prostate 
and the feasibility of definitive treatment by extemal beam mega-
voltage inadiation. 
Therapeutic Options for Early 
Stage Prostate Cancer 
Although many urologic oncologists agree that patients with 
locally advanced prostatic cancer (stages B2 and C) may be best 
treated with definitive extemal beam radiation therapy, the use 
of radiotherapy in the treatment of early stages of disease (i.e.. 
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Figure—Isodose distribution ofthe radiation dose, taken at the 
level of the prostate (A, B, C, D represent an isodose line of 
6,600 cGy, 6,400 cGy, 5,000 cGy. and 4,000 cGy, respectively). 
A2 and B1) has been less well defined. Radical prostatectomy is 
a well-established therapy for early localized prostate cancer. In 
particular, patients with stage Bl cancer with low-grade histol-
ogy (eg,, Gleason score of less than 6) are the ideal group for 
radical surgery, tf patients are not candidates for radical surgery 
for either medical or other reasons, they are eligible for radical 
radiation therapy. Such patients are then evaluated for either ra-
dioactive interstitial implant or extemal beam radiation therapy. 
Radionuclide hrachytherapy offers several advantages over 
extemal beam radiation therapy. These include 1) delivery of a 
high local dose to the prostate over several months, 2) limited 
injury to the adjacent organs because ofthe geometric fall-off of 
the radiation dose with distance from the seeds as well as attenu-
ation by tissue, 3) completion of therapy at one setting, and 4) 
the opportunity at the time of implantation to stage the disease 
accurately by bilateral pelvic lymphadenectomy. Indications for 
radionuclide hrachytherapy (e.g., iodine-125 or palladium-103) 
are usually comparable to those for a radical prostatectomy (i.e., 
patients with stage Bt or B2 with tow-grade histology). In re-
cent years, substantial progress has been made to improve distri-
bution of the radiation dose within the prostate using computed 
tomography (CT) or transrectal ultrasound to guide implanta-
tion. These approaches are technically far superior to conven-
tional retropubic implantation (9-15). We have successfully 
tteated several early stage prostate cancers with a perineal im-
plantation technique using CT-based guidance. 
Most patients with early stage prostatic cancers (i.e., stages 
A2, B l , and B2 with high-grade histology) are excellent candi-
dates for extemal beam radiation therapy. A high-energy exter-
nal beam is essential to deliver the dose of radiation needed to 
achieve tumor control and to minimize damage to the adjacent 
normal tissue. Extemal beam treatment of prostate cancer must 
involve a high-energy linear accelerator (usually more than 10 
MeV x-rays), the use of simulation, and complex field anange-
ments (usually four or more fields), as well as optimization in 
the radiation dosimetry. CT scan and other imaging data are 
used to achieve this optimized treatment plan (Figure). The 
complex multiple field technique permits delivery of a curative 
dose of radiation (65 to 70 Gy) to the prostate with a minimal 
normal tissue morbidity. 
The results of several large retrospective series (16-18) re-
porting extemal beam radiotherapy of the prostate cancer are 
presented in Table 1. Survival rates for treated patients with 
stage A disease at 5 and 10 years are 82%-95% and 70%-85%, 
respectively. Of patients with stage B tumors, 75% survived 5 
years and 40% to 55% survived 10 years. Through 15 years of 
follow-up, overall survival in the patients treated surgically 
(19,20) and those in stage Bl treated with extemal beam radio-
therapy (16) did not deviate significantly from each other (rates 
of 51%, 57%, and 52%, respectively). 
Perez et al (17) reported a 70% disease-specific 10-year sur-
vival rate for stage A2 and 55% for stage B disease. The 10-year 
disease-specific rates in the pattems of care studies (PCS) in the 
United States are comparable (77% for stage A and 40% for 
stage B) (18). 
Treatment of Locally Advanced Prostate 
Cancer (Stage C, Dl, or T3-T4) 
In all the series of prostate cancer presented to the National 
Institutes of Health Consensus Development Conference (June 
1987), the initial size or stage of the tumor at diagnosis was the 
most significant factor in predicting the outcome (21). In pa-
tients who presented with a palpable tumor extending outside 
the prostate (stages T3 and T4 or stage C), local recurrence rates 
Series 
Table 1 
Survival Results With External Beam Radiation Therapy 
in Localized Disease (Stages A and B) 
Overall (Actuarial) Survival (%) 
5 years 10 years 15 years 
Disease-Specific Survival (%) 
5 years 10 years 15 years 
Bagshaw A 95 75 45 95 85 85 
et al(I6) Bl 80 6(1 .x5 85 75 64 
B2 80 55 33 85 65 45 
Perez etal (17) A2 79 67 82 7(1 
i'. 76 ?o 75 55 
Hantcs et al (18) A 83 (-.2 84 77 
(POC) B 73 46 fi6 4(1 
POC = Patterns of care studies in the United Slates. 
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were 25% to 40% and the probability of progression with distant 
metastases was 50% to 75% (21). In contrast to the results 
achieved from the management of stages A and B disease, lO-
year survival after presentation with locally advanced prostate 
cancer is a disappointing 20% to 40% (22-25). The tumor con-
trol rate by radiation therapy is inversely proportional to the size 
of the tumor and higher doses are necessary for larger tumors 
(26). External beam radiotherapy can be applied to periprostatic 
extension of cancer that cannot be removed surgically (stage C). 
Doses exceeding 7,000 cGy are necessary to minimize local re-
cunences (27). A significant problem with these data is the inac-
curacy of clinical staging without surgery; the local lesion may 
be misstaged and the lymph nodes understaged in the absence of 
lymphadenopathy. 
Optimal management of locally advanced prostate cancer 
with pelvic lymph node metastases (stage Dt or T4) is a thera-
peutic enigma. Regional lymph node involvement worsens the 
prognosis, for the risk of distant spread in these patients is re-
portedly 75% to 80% (28). Accordingly, a broad range of treat-
ments have been evaluated; early initiation of chemotherapy; 
the combination of radiotherapy with hormonal manipulation; 
and prostatectomy with interstitial inadiation. No prefened reg-
imen has been defined, and detailed discussion of these modali-
ties is beyond the scope of this review. Data conceming radia-
tion efficacy in patients with lymph node involvement are 
scarce However, Bagshaw (29) reported that 14% to 18% (de-
pending on radiation portals) of patients survived for more than 
5 years without evidence of cancer. In 1982 Paulson et al (30) 
evaluated 41 patients with surgical stage Dl disease who were 
treated with extended field radiation alone. A total of 32% were 
alive and disease-free at 60 months. Although recent data using 
a mixed beam (neutron/photon) regimen for patients with lo-
cally advanced (stages C and Dl) carcinoma of the prostate have 
shown superior results to standard photon therapy (locoregional 
control at 5 years, 81% versus 60%), the study included a rela-
tively small number of patients and the follow-up was relatively 
short (31), 
tn an effort to improve local tumor control and to increase the 
survival rates of patients with locally advanced prostate cancer, 
we devised a novel approach combining antimitotic chemother-
apeutic agents and extemal beam radiation therapy. Based on 
the growing understanding of the mechanism of action of anti-
mitotic agents (e.g., estramustine phosphate and vinblastine sul-
fate), we initiated a pha.se tt study of concomitant administration 
of estramustine and vinblastine in combination with extemal 
beam radiation therapy. Radiobiological studies indicate that 
cells accumulated in the G2 phase due to the drug-induced mi-
totic block would be highly sensitive to fractionated radiation 
therapy, resulting in enhanced tumor cell kill. To date, the toler-
ance of patients to this regimen has been excellent. 
Adjuvant Radiation Therapy 
After Prostatectomy 
for Pathologic Stage C Cancer 
Postoperative radiotherapy has not been used so commonly 
for cancer of the prostate as for other cancers but has been used 
Table 2 
Postprostatectomy Radiation Therapy 
Before Local Recurrence 
Series 
Number of Ltxally Controlled/ 
Number of Patients 
Five-Year 
Survival (%) 
Rosen et al (32) 15/16 94 
Gibbons et al (33) 21/22 73 
Hanks & Dawson (34) 10/10 86 
Ray et al (35) 10/13 57 
Pilepich et al (36) 18/18 4.-S 
Total 74/79 (94%) 
in small groups of patients at several centers. For the most part, 
this treatment has been utilized in patients after incomplete sur-
gery or in those with pathologic stage C malignancy (surgical 
margin positive in histological examination, microscopic inva-
sion through the capsule or infiltration of the seminal vesicles), 
tn these patients, local recurrence would be expected in 20% to 
45% after surgery atone The locat control of prostate cancer 
when adjuvant inadiation was given either before or after local 
recunence is tabulated in Tables 2 and 3 (32-36). Control was 
obtained in 94% of the patients treated shortly after surgery but 
only in 70% of patients who were treated after clinical recur-
rence. From these data one can conclude that immediate radio-
therapy improves the chance of cure after incomplete surgery. 
However, there were no significant differences in survival be-
tween the inadiated and noninadiated pathologic stage C pa-
tients. Therefore, the Southwestem Oncology Group is conduct-
ing a prospective randomized study comparing observation ver-
sus postoperative radiation therapy for pathologic stage C pros-
tate cancer. 
Assessment of Local Control: Significance 
of Post Radiotherapy Biopsy 
In the majority of cases, cancer of the prostate is a slowly 
growing tumor but simultaneously is a slowly regressing tumor. 
Until there is better systemic management of prostate cancer, lo-
cal control is the only realistic goal of local therapy, whether ra-
diation treatment or surgery. 
Avoiding the distressing symptoms which resutt from local 
failure contributes to quality of life and is an important goal of 
Table 3 
Postprostatectomy Radiation Therapy 
After Local Recurrence 
Series 
Number of Locally Controlled/ 
Number of Patients 
Five-Year 
Survival (%) 
Rosen et al(32) 10/13 15 
Gibbons et al (33) 16/23 40 
Hanks & Dawson (34) 8/10 71 
Ray et al (35) 11/19 40 
Total 45/65 (70%) 
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radiation therapy (37). Assessment of local results immediately 
after radiotherapy may be misleading because it may require 
many months after treatment to achieve complete regression. 
Perez et at (38,39) found complete regression three months after 
radiotherapy in 44% of stage B and 22% of stage C patients, 
whereas the ultimate local control rates were 89% and 66%, re-
spectively. 
Cox and Kline (40) performed serial biopsies of the prostate 
in patients with stage C disease after extemal beam radiation 
therapy. The number of positive biopsies fell from 66% three to 
six months after therapy to 19% two to three years later. They 
found that after adequate inadiation, positive biopsies per-
formed even one to two years later did not predict the ultimate 
result. In contrast to this series, a study of prostate biopsies 6 to 
36 months after completion of radiotherapy does show a cone-
lation between posttive posttreatment biopsy and progressive 
disease (41), If any biopsy was positive, 60% of the patients 
eventually developed local recunence; with negative biopsies, 
only 19% developed local recunence. This issue will not be re-
solved until a prospective trial is conducted. However, periodic 
digital examination is considered adequate to evaluate local 
control, and biopsy can be limited to those patients who have 
clinical evidence of progression. 
Prostate-Specific Antigen as 
a New Tumor Marker 
Prostate-specific antigen (PSA) is a useful tumor marker for 
monitoring response to radiotherapy in patients with prostate 
cancer. The test can identify patients at risk for failure, allowing 
early intervention with hormone therapy or chemotherapy, PSA 
is far superior to acid phosphatase in predicting treatment fail-
ure The decline in serum levels of PSA after "definitive" radia-
tion for localized prostate cancer is much delayed when com-
pared to the drop after surgical excision, but it is nonetheless 
useful prognostically. In the Stanford .series serial values were 
stable after one year in 49% ofthe patients but were increasing 
in 51% (42,43), Relapse should be suspected if the PSA is not 
normal within six months after completion of radiation therapy. 
Future studies may further define the role of PSA as an indi-
cation of early relapse of prostate cancer. 
Summary and Future Prospects 
The efficacy of radiation therapy in the treatment of early 
stages of prostate cancer has been well established. In cancers 
limited to the prostate gland, results of radiotherapy are as good 
as that of radical prostatectomy. Because of the comparable 
long-term tumor control rates, patients with early stages of pros-
tate cancer have various options for curative treatment. These 
include radical prostatectomy, radionuclide hrachytherapy, and 
extemal beam radiation therapy. Stage of the tumor, histologic 
grade, size of the primary tumor, and overall medical conditions 
of the patient must alt be considered in selecting a therapeutic 
modality. 
Considerable progress has been made in delivering high tu-
moricidal doses of radiation using extemal beam therapy. 
Highly focused precision delivery of radiation is feasible he-
cause of improved imaging techniques and complex multiple 
field anangements. There has also been significant technical 
progress in the use of hrachytherapy. Radioiodine-125 can be 
implanted successfully in most patients with early stage, low-
grade prostate cancers utilizing a CT-guided transperineal ap-
proach. 
For locally advanced stages of prostate cancer, a variety of 
new technological and radiobiological approaches are being 
evaluated at our institution. These include the use of a multileaf 
collimated linear accelerator to deliver three-dimensional exter-
nal beam radiotherapy. Evaluation of concomitant chemother-
apy and radiotherapy is well under way for patients with local-
ized prostatic cancer of high-grade histology. Other experimen-
tal modalities such as hyperthermia, photodynamic therapy, and 
radiation chemical sensitizers may prove to be of value. 
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